# Contents


## 1 Epidemiology

**Introduction** . . . . . 2

**Definition** . . . . . 2

Gender-Specific Mortality Rates . . . . . 3
Morbidity and Mortality with Respect to Age and Gender . . . . . 4
Perception . . . . . 6
Mortality in Myocardial Infarction: Comparison Between Women and Men . . . . . 6
International Comparisons . . . . . 7

**The "MONItoring Cardiovascular Disease" Project of the WHO (WHO MONICA Project)** . . . . . 10

## 2 Cardiovascular Risk Factors and the Development of Coronary Heart Disease in Women

**Smoking** . . . . . 16

**Dyslipidemia** . . . . . 17

**Lipoprotein (a)** . . . . . 19

**Diabetes Mellitus** . . . . . 20

**Insulin Resistance and Polycystic Ovary Syndrome** . . . . . 21

**Family History of Coronary Heart Disease or Genetic Disposition** . . . . . 23

**Hypertension** . . . . . 23

**Sedentary Lifestyle** . . . . . 23

**Obesity** . . . . . 25

**Homocysteine** . . . . . 26

**High sensitivity C-reactive Protein** . . . . . 27

**Risk Factors Unique to Women** . . . . . 28

Menopause . . . . . 28
Oral Contraception . . . . . 29

## 3 Pathophysiology of Coronary Heart Disease and the Effects of Estrogen

**Basics** . . . . . 36

Plaque Formation and Significance of Plaques in CHD . . . . . 36

**Effects of Estrogen** . . . . . 38

Effect of Estrogen on Vascular Reactivity and Endothelial Function . . . . . 39
Effect of Estrogen on Lipid Metabolism . . . . . 41
Antioxidative Effect of Estrogen . . . . . 42
Effect of Estrogen on Inflammation . . . . . 43
Effect of Estrogen on Hemostasis . . . . . 43

## 4 Stable Angina

**Definition and Pathophysiology of Angina Pectoris** . . . . . 48

**Diagnosis Based on Symptoms** . . . . . 49

Prinzmetal's or Variant Angina . . . . . 50
Syndrome X . . . . . 51

**Diagnostic Evaluation** . . . . . 52

Electrocardiogram . . . . . 52

Stress Testing, Including Stress Echocardiography and Nuclear Imaging . . . 52
*Determination of Pretest Probability for CHD* . . . 52
*Selection of Stress Test* . . . 53
*Stress ECG* . . . 53
*Nuclear Imaging* . . . 55
*Stress Echocardiography* . . . 56
*Pharmacological Stress Tests* . . . 58
Electron Beam Computed Tomography . . . 61
Magnetic Resonance Imaging . . . 61
Diagnostic Cardiac Catheterization . . . 61
Gender Differences in the Use of Diagnostic Cardiac Catheterizations and Percutaneous Coronary Intervention . . . 62

**Medical Management** . . . 64

Beta-blockers . . . 64
Nitrate . . . 66
Calcium Channel Blockers . . . 66

**Percutaneous Coronary Intervention for Stable Angina** . . . 67

Gender-Specific Success and Complication Rates for Balloon Angioplasty . . . 69
Gender-Specific Success and Complication Rates for Coronary Intervention with Stent Implantation . . . 71
Restenosis . . . 74
Rotablator Therapy, Directional Coronary Atherectomy, Laser Therapy . . . 74
Multivessel Coronary Intervention – When PCI? When Bypass Surgery? . . . 75

## 5 Acute Myocardial Infarction

**Progression from Stable Coronary Heart Disease to Myocardial Infarction** . . . 84

**Epidemiology of Acute Myocardial Infarction** . . . 85

**Pathophysiology** . . . 87

**Clinical Presentation of Acute Myocardial Infarction** . . . . . 89
Silent Myocardial Infarction . . . . . 89
Symptomatic Myocardial Infarction . . . . . 90

**Criteria for the Diagnosis of Acute Myocardial Infarction** . . . 90
Clinical Presentation . . . . . 90
Electrocardiogram . . . . . 91
Serum Markers of Cardiac Damage . . . . . 91
Creatine Kinase and the CK Isoenzyme CK-MB . . . . . 91
Troponin T and I . . . . . 92

**Therapy** . . . . . 92
Revascularization . . . . . 93
*Thrombolytic Therapy* . . . . . 93
*Primary Percutaneous Transluminal Coronary Angioplasty* . . 94
*Thrombolysis Versus Primary PTCA* . . . . . 96
*Rescue PTCA after Thrombolysis of Acute Myocardial Infarction* . . . . . 97
Medical Therapy of Acute Myocardial Infarction . . . . . 98
*Aspirin* . . . . . 99
*Beta-blockers* . . . . . 99
*Unfractionated Heparin* . . . . . 99
*Calcium Channel Blockers* . . . . . 100
*ACE Inhibitors* . . . . . 100
*Nitrates* . . . . . 100

**Complications** . . . . . 101

**Prognosis** . . . . . 102
Mortality in Acute Myocardial Infarction (With and Without Thrombolysis) . . . . . 103
Mortality in the Pre-thrombolytic Era (Mid-1960s to Early-1980s) . . . . . 105
Mortality in the Thrombolytic Era (1980 to Present) . . . . . 105

**Influence of Gender on the Referral for Coronary Angiography in Patients with Acute Myocardial Infarction** . . . . . 107

## 6 Acute Coronary Syndromes

**Non-ST-Elevation Myocardial Infarction/Unstable Angina** . . 116

**Definition** . . . . . 118

**Presentation** . . . . . 118

**Diagnosis** . . . . . 119

**Therapy** . . . . . 120

Medical Therapy . . . . . 120

*Aspirin* . . . . . 120

*Unfractionated Heparin* . . . . . 121

*Low-Molecular-Weight Heparin* . . . . . 121

*Glycoprotein IIb/IIIa Receptor Antagonists* . . . . . 122

*Nitrates* . . . . . 127

*Beta-blocker* . . . . . 127

*Calcium Channel Blocker* . . . . . 127

Interventional Therapy . . . . . 127

## 7 Coronary Artery Bypass Surgery

**Operative Mortality** . . . . . 134

**Complications Associated with CABG** . . . . . 138

**Long-Term Outcomes** . . . . . 139

**Indication for CABG Surgery** . . . . . 140

**Comparison of CABG with Multivessel Angioplasty** . . . . . 141

## 8 Primary and Secondary Prevention of Coronary Heart Disease

**Class I Interventions** . . . . . 148
Treatment of Hyperlipidemia . . . . . 148
*Diet* . . . . . 149
*Medical Therapy of Dyslipidemia* . . . . . 151
*Primary Prevention Trials* . . . . . 151
*Primary Prevention with Estrogen* . . . . . 151
*Secondary Prevention Trials with Statins* . . . . . 152
*Secondary Prevention Trials with Medications Other Than Statins* . . . . . 154
Treatment of Hypertension . . . . . 155
Aspirin . . . . . 160
*Primary Prevention of CAD with Aspirin* . . . . . 160
*Secondary Prevention with Aspirin* . . . . . 160

**Class II Interventions** . . . . . 161
Physical Activity . . . . . 161
*Primary Prevention Studies* . . . . . 162
*Secondary Prevention Studies* . . . . . 162
Weight Reduction . . . . . 164
Alcohol . . . . . 164

**Class III Interventions** . . . . . 166
Antioxidants . . . . . 166
*Vitamins E and C* . . . . . 166
*Beta-carotene* . . . . . 168

## 9 Hormone Replacement Therapy

**Hormone Replacement Therapy and Prevention of Coronary Heart Disease** . . . . . 176

**Observational Studies for Primary and Secondary Prevention** . . . . . 177

**Randomized Primary Prevention Trials** . . . . . 178

**Randomized Secondary Prevention Trials** . . . . . 180

**Clinical Implications of Hormone Replacement Therapy** . . . 185

Combination Therapy . . . . . 187
Risk of Breast Cancer with HRT. . . . . 187
Risk of Ovarian Cancer with HRT . . . . . 190
Risk of Endometrial Cancer with HRT . . . . . 190
Risk of Deep Vein Thrombosis and Thromboembolic Events . . 191
Estrogen and High Sensitivity C-reactive Protein . . . . . 192

**Biological Mechanisms of Hormone Replacement Therapy** . 193

Lipids and Antioxidant Effects of Estrogen . . . . . 193
Glucose Metabolism . . . . . 194
Hemostasis . . . . . 195
Vascular Reactivity . . . . . 195
Impact on Markers of Inflammation . . . . . 196
Selective Estrogen Receptor Modulators . . . . . 196
Soy Protein . . . . . 198

## 10 Future Directions

http://www.springer.com/978-3-540-00128-7

Coronary Heart Disease in Women
Prevention - Diagnosis - Therapy
von der Lohe, E.
2003, XVI, 210 p. 47 illus., Softcover
ISBN: 978-3-540-00128-7